OPN-6602 is Currently in a Phase 1 Clinical Trial for Relapsed/Refractory Multiple Myeloma SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–February 12, 2025– Opna Bio, a clinical-stage biopharmaceutical ...
OPN-6602 received orphan drug designation for relapsed or refractory multiple myeloma, highlighting its therapeutic potential. The FDA's orphan drug designation offers benefits like tax credits and ...
In the modified intent-to-treat population, the rate of post-operative complications at 30 days was 37% in the RAPN arm and 46% in the OPN arm. Patients with intermediate- or high-complexity renal ...
SIS Medical AG Welcomes the Results of the VICTORY Trial Demonstrating Non-inferiority of OPN NC to Intravascular Lithotrispy (IVL) for Lesion Preparation and Stent Expansion in Severely Calcified ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results